

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PROSTEN HEALTH HOLDINGS LIMITED

長達健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8026)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board of directors (“**Board**”) of Prosten Health Holdings Limited (“**Company**”) would like to announce that Mr. Wen Xingcheng has been appointed by the Board as executive director of the Company with effect from 3 April 2017.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is delighted to announce that Mr. Wen Xingcheng has been appointed by the Board as executive director of the Company with effect from 3 April 2017.

Mr. Wen Xingcheng (溫興程) (“**Mr. Wen**”) aged 30, graduated from Shenzhen Shende Technical School (深圳市深德技工學校) with an associated degree in 2009. He worked at Maoming Dianbai Zhi Wei Long Food Co., Ltd. (茂名市電白縣智偉龍食品有限公司) as a salesman, mainly responsible for the development of food processing and sales channels, between February 2012 and December 2012; and at Maoming Zhi Wei Long Energy Co., Ltd. (茂名市智偉龍能源有限公司) as manager, in charge of coal wholesale and distribution, between January 2013 and December 2014. He has been working at Maoming Zhi Wei Long Business Co., Ltd. (茂名市智偉龍商業有限公司) as manager, responsible for the management of processing and sale of agricultural by-product and medicinal materials and development of new projects, since January 2015. Mr. Wen is the nephew of Ms. Shenjing, a substantial shareholder of the Company.

Save as disclosed herein, as at the date of this announcement, (i) Mr. Wen does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) does not have any interests in the shares or underlying shares in the Company within the meaning of Part XV of the SFO; (iii) does not hold other positions with the Company and its subsidiaries; and (iv) has not held any directorship in any public listed companies in the last three years preceding the date of this announcement or any other major appointments or professional qualifications.

Mr. Wen has entered into a service agreement with the Company on 3 April 2017. There is no fixed term for his appointment, which shall be continuous until terminated by either party by serving on the other party not less than three months' prior notice in writing. Notwithstanding the foregoing, he is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. In particular, Mr. Wen, as appointed by the Board, shall hold office until the next following general meeting of the Company and be eligible to offer himself for re-election at such meeting.

According to the service agreement, Mr. Wen is entitled to director's emolument of HK\$240,000 per annum payable monthly by twelve equal installments, which is subject to annual review with such increment (if any) at such rate to be determined by the remuneration committee of the Company and approved by a majority in number of the disinterested members of the Board. Further, in respect of each financial year during his appointment, Mr. Wen may receive a discretionary bonus of a sum (if any) to be determined and approved by the Board at its absolute discretion having regard to the operating results of the Company and its subsidiaries and the performance of Mr. Wen himself. The amount of discretionary bonus payable to him shall similarly be decided by the remuneration committee of the Company and approved by a majority in number of the disinterested members of the Board. The above remuneration package is determined by arm's length negotiation between Mr. Wen and the Company, and with reference to his duties and responsibilities, his qualifications and experience, the prevailing market conditions and the Company's remuneration policy.

Save as disclosed above, there is no information relating to Mr. Wen that is required to be disclosed pursuant to paragraphs (h) to (v) of Rule 17.50(2) of the Rules Governing the Listing of Securities on the Growth Enterprise Market (“GEM”) of The Stock Exchange of Hong Kong Limited (“GEM Listing Rules”) nor is there any matter about him that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend a warm welcome to Mr. Wen.

By order of the Board
PROSTEN HEALTH HOLDINGS LIMITED
Xu Zhigang
Chairman

Hong Kong, 3 April 2017

As at the date of this announcement, the Board comprises the following Directors:

Mr. Xu Zhigang (Executive Director (Chairman))
Mr. Han Jun (Executive Director)
Mr. Shi Liangsheng (Executive Director)
Mr. Wen Xingcheng (Executive Director)
Mr. Chen Weixi (Non-Executive Director)
Mr. Poon Yan Wai (Independent Non-Executive Director)
Mr. Xu Xiaoping (Independent Non-Executive Director)
Mr. Lam Kwok Cheong (Independent Non-Executive Director)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Company Announcements” page for at least 7 days from the date of its posting and the Company’s website at www.prosten.com.